Octagon Capital Advisors LP
Filing Date
Global Rank
#1,870
/ 8,588
▲ 268
Top Industry
Biotechnology
96.3%
3Y Alpha vs SPY
-10.6%
Period ended 3 months ago
Filed May 15, 2026 · 34d
22 quarters · since Dec 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+34.2%
SPY
+76.8%
Annualised alpha
-10.6%
Max drawdown
−55.4%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
29 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
18.1%
+4.5 pts
Top 5
48.4%
−1.7 pts
Top 10
68.6%
−4.5 pts
HHI
726
Diversified−2
Portfolio Trend
22 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $903,609,411 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PALI | Palisade Bio, Inc. | +708,419 | 10,276,317 | $17,983,554 | |
| OCUL | Ocular Therapeutix, Inc | +543,000 | 3,166,600 | $26,821,102 | |
| DTIL | Precision Biosciences Inc | +318,737 | 2,236,732 | $12,302,026 | |
| ALMS | Alumis Inc. | +300,000 | 2,830,700 | $62,360,321 | |
| KALV | KalVista Pharmaceuticals, Inc. | +176,667 | 1,450,000 | $29,188,500 | |
| BIOA | BioAge Labs, Inc. | +150,000 | 1,748,000 | $30,572,520 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
9 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | −6,165,371 | 7,750,000 | $2,549,750 | |
| TRVI | Trevi Therapeutics, Inc. | −1,330,000 | 1,485,000 | $17,716,050 | |
| LXEO | Lexeo Therapeutics, Inc. | −625,000 | 1,100,000 | $6,314,000 | |
| PHVS | Pharvaris N.V. | −506,465 | 165,000 | $4,661,250 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | −470,000 | 1,946,667 | $163,364,294 | |
| EVMN | Evommune, Inc. | −356,528 | 143,472 | $3,298,421 | |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | −324,110 | 719,000 | $6,435,050 | |
| KYMR | Kymera Therapeutics, Inc. | −110,000 | 425,000 | $35,398,250 | |
| ABVX | Abivax S.A. | −79,000 | 677,000 | $75,383,950 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | 2,440,000 | $46,116,000 | |
| MIRM | Mirum Pharmaceuticals, Inc. | 338,900 | $31,307,582 | |
| XENE | Xenon Pharmaceuticals Inc. | 490,000 | $28,493,500 | |
| TERN | Terns Pharmaceuticals, Inc. | 530,000 | $27,941,600 | |
| IRON | Disc Medicine, Inc. | 270,000 | $17,263,800 | |
| AKTS | Aktis Oncology, Inc. | 960,847 | $17,189,552 | |
| CNTX | Context Therapeutics Inc. | 5,250,000 | $13,755,000 | |
| CATX | Perspective Therapeutics, Inc. | 791,555 | $3,300,784 | |
| No positions match the current search. | ||||
29 positions ·
$903,609,411 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| GOSS |
Gossamer Bio, Inc.
Healthcare
|
Reduced | 7,750,000 | $2,549,750 | 0.28% | |
| EVMN |
Evommune, Inc.
Healthcare
|
Reduced | 143,472 | $3,298,421 | 0.37% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
NEW | 791,555 | $3,300,784 | 0.37% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Reduced | 165,000 | $4,661,250 | 0.52% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Reduced | 1,100,000 | $6,314,000 | 0.70% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Reduced | 719,000 | $6,435,050 | 0.71% | |
| UNCY |
Unicycive Therapeutics, Inc.
Healthcare
|
Reduced | 1,000,000 | $6,580,000 | 0.73% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
Held | 574,200 | $11,995,038 | 1.33% | |
| DTIL |
Precision Biosciences Inc
Healthcare
|
Reduced | 2,236,732 | $12,302,026 | 1.36% | |
| CNTX |
Context Therapeutics Inc.
Healthcare
|
NEW | 5,250,000 | $13,755,000 | 1.52% | |
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
NEW | 960,847 | $17,189,552 | 1.90% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
NEW | 270,000 | $17,263,800 | 1.91% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 1,485,000 | $17,716,050 | 1.96% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
Added | 10,276,317 | $17,983,554 | 1.99% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Added | 3,166,600 | $26,821,102 | 2.97% | |
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
NEW | 530,000 | $27,941,600 | 3.09% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
NEW | 490,000 | $28,493,500 | 3.15% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Added | 1,450,000 | $29,188,500 | 3.23% | |
| CNTA |
Centessa Pharmaceuticals plc
Healthcare
|
Held | 750,000 | $29,790,000 | 3.30% | |
| BIOA |
BioAge Labs, Inc.
Healthcare
|
Added | 1,748,000 | $30,572,520 | 3.38% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
NEW | 338,900 | $31,307,582 | 3.46% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 425,000 | $35,398,250 | 3.92% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Held | 8,859,911 | $39,603,802 | 4.38% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
Held | 1,971,054 | $45,472,215 | 5.03% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 2,440,000 | $46,116,000 | 5.10% | |
| ALMS |
Alumis Inc.
Healthcare
|
Added | 2,830,700 | $62,360,321 | 6.90% | |
| ABVX |
Abivax S.A.
Healthcare
|
Reduced | 677,000 | $75,383,950 | 8.34% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 2,350,000 | $90,451,500 | 10.01% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Reduced | 1,946,667 | $163,364,294 | 18.08% |